Stereotactic body radiotherapy for colorectal lung oligometastases: Preliminary single-institution results

Journal of B.U.ON.

Volumn 20, Issue 1, 2015, Pages 158-165

  Carvajal, Claudia ^a   Navarro Martin, Arturo ^b   Cacicedo, Jon ^a   Ramos, Ricard ^a   Guedea, Ferran ^b  

^a HOSPITAL DE CRUCES   (Spain)

^b Oncology Department   (Spain)

Author keywords

Colorectal cancer; Lung cancer; Oligometasta ses; Stereotactic radiotherapy

Indexed keywords

DEXAMETHASONE;

ACUTE TOXICITY; ADULT; AGED; ARTICLE; ASTHENIA; ASYMPTOMATIC DISEASE; BONE METASTASIS; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SPECIFIC SURVIVAL; CANCER SURGERY; CAUSE SPECIFIC SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; CORTICOSTEROID THERAPY; DISTANT METASTASIS; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LUNG OLIGOMETASTASIS; LUNG SURGERY; MALE; MULTILEAF COLLIMATOR; OUTCOMES RESEARCH; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RADIATION DERMATITIS; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION PNEUMONIA; RADIATION RESPONSE; RADIOTHERAPY UNIT; SINGLE DRUG DOSE; STEREOTACTIC BODY RADIATION THERAPY; SYSTEMIC DISEASE; SYSTEMIC THERAPY; ADVERSE EFFECTS; COLORECTAL TUMOR; DISEASE COURSE; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; LUNG NEOPLASMS; METASTASIS RESECTION; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RADIOSURGERY; REMISSION; RISK FACTOR; SECONDARY; SPAIN; TIME; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; FEASIBILITY STUDIES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; METASTASECTOMY; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RADIOSURGERY; REMISSION INDUCTION; RISK FACTORS; SPAIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84928695961     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Almaghrabi MY, Supiot S, Paris F, Mahe MA, Rio E. Stereotactic body radiation therapy for abdominal oligometastases: A biological. Radiat Oncol (London, England) 2012;7:126.
2. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol 1995;13:8-10.
3. Weichselbaum RR, Hellman S. Oligometastases revisited Nat Rev Clin Oncol 2011;8:378-382.
4. Niibe Y, Hayakawa K. Oligometastases and oligo-re- currence: The new era of cancer therapy. Jpn J Clin Oncol 2010;40:107-111.
5. Siva S, MacManus M, Ball D. Stereotactic radiotherapy for pulmonary oligometastases. J Thorac Oncol 2010;5:1091-1099.
6. Treasure T. Oligometastatic cancer: An entity, a useful concept, or a therapeutic opportunity? J R Soc Med 2012;105:242-246.
7. Schefter TE, Kavanagh BD, Raben D. A phase I/II trial of stereotactic body radiation therapy (SBRT) for lung metastases: initial report of dose escalation and early toxicity. Int J Radiat Oncol Biol Phys 2006;66:120-127.
8. Tree AC, Khoo VS, Eeles RA et al. Stereotactic body radiotherapy for oligometastases. Lancet Oncol 2013;14:e28-37.
9. Corbin KS, Hellman S, Weichselbaum RR. Extracra nial Oligometastases: A Subset of Metastases Curable With Stereotactic Radiotherapy. J Clin Oncol 2013;31:1384-1390.
10. Timmerman R, Paulus R, Galvin J et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010;303:1070-1076.
11. Navarro-Martin A. Risk Adapted SABR (SABR) Stage INSCLC and Lung Metastases. In :ClinicalTrials. gov[Internet].Bethesda(MD): National Library of Medicine (US) 2000- cited 21 May 2014. Available from:http//Clinicaltrials.gov/show/NCT01823003 NLM IDENTIFIER: NCT NCT01823003.
12. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours : Revised RECIST guideline ( version 1.1 ). Eur J Cancer 2008;45:228-247.
13. Kang JK, Kim MS, Kim JH et al. Oligometastases confined in one organ from colorectal cancer treated by SBRT. Clin Exp Metastasis 2010;27:273-278.
14. Long-term results of lung metastasectomy: Prognostic analyses based on 5206 cases. The International Registry of Lung Metastases. J Thorac Cardiovasc Surg 1997;113:37-49.
15. Pfannschmidt J, Dienemann H, Hoffmann H. Surgical resection of pulmonary metastases from colorectal cancer: A systematic review of published series. Ann Thorac Surg 2007;84;324-338.
16. Sternberg DI, Sonett JR. Surgical therapy of lung metastases. Semin Oncol 2007;34:186-196.
17. Bilal H, Mahmood S, Rajashanker B, Shah R. Is radiofrequency ablation more effective than stereotactic ablative radiotherapy in patients with early stage medically inoperable non-small cellung cancer? Interact Cardiovasc Thorac Surg 2012;15:258-265.
18. Hatime M, Elmorabit B, Elkhoti Y, Touch S, Tanguy R, Mornex F. Oligometastatic disease, a new concept: Stereotactic irradiation for lung metastases. Literature review. Cancer Radiother 2012;16:351-357.
19. Corbin K, Hellman S, Weichselbaum RR. Extracranial Oligometastases: A Subset of Metastases Curable With Stereotactic Radiotherapy. J Clin Oncol 2013;31:1384-1390.
20. Osti MF, Carnevale A, Valeriani M et al. Clinical outcomes of single dose stereotactic radiotherapy for lung metastases. Clin Lung Cancer 2013;14:699-703.
21. Kong C, Guo WJ, Zha WW et al. A new index comparable to BED for evaluating the biological efficacy of hypofractionated radiotherapy schemes on early stage non-small cell lung cancer: Analysis of data from the literature. Lung Cancer 2014;84:7-12.
22. Lo SS, Fakiris AJ, Chang EL et al. Stereotactic body radiation therapy: A novel treatment modality. Nat Rev Clin Oncol 2010;7:44-54.
23. Rusthoven KE, Kavanagh BD, Burri SH et al. Multi-Institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Lung Metastases. J Clin Oncol 2009;27:1579-1584.
24. Widder J, Klinkenberg TJ, Ubbels JF, Wiegman EM, Groen HJ, Langendijk JA. Pulmonary oligometastases: Metastasectomy or stereotactic ablative radiotherapy? Radiother Oncol 2013;107:409-413.
25. Takeda A, Kunieda E, Ohashi T, Aoki Y, Koike N, Takeda T. Stereotactic body radiotherapy (SBRT) for oli gometastatic lung tumors from colorectal cancer and other primary cancers in comparison with primary lung cancer. Radiother Oncol 2011;101:255-259.
26. Milano MT, Katz AW, Zhang H, Okunieff P. Oligometastases treated with stereotactic body radiotherapy: long- Term follow-up of prospective study. Int J Radiat Oncol Biol Phys 2012;83:878-886.
27. Oh D, Ahn YC, Seo JM et al. Potentially curative stereotactic body radiation therapy (SBRT) for single or oligometastasis to the lung. Acta Oncol 2012;51:596-602.
28. Wulf J, Baier K, Mueller G, Flentje MP. Dose-response in stereotactic irradiation of lung tumors. Radiother Oncol 2005;77:83-87.
29. Navarria P, Ascolese AM, Tomatis S et al. Stereotactic body radiotherapy ( SBRT) in lung oligometastatic patients : role of local treatments. Radiat Oncol 2014;9:1-8.
30. Bae SH, Kim M-SS, Cho CK et al. High dose stereotactic body radiotherapy using three fractions for colorectal oligometastases. J Surg Oncol 2012;106:138-143.
31. Ricardi U, Riccardo A, Guarneri A et al. Lung cancer stereotactic body radiation therapy for lung metastases. Lung Cancer 2012;75:77-81.
32. Ricardi U, Filippi AR, Franco P. New concepts and insights into the role of radiation therapy in extracranial metastatic disease. Expert Rev Anticancer Ther 2013;13:1145-1155.
33. De Vin T, Engels B, Gevaert T, Storme G, De Ridder M. Stereotactic radiotherapy for oligometastatic cancer: A prognostic model for survival. Ann Oncol 2014;25:467-471.